Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1991 Mar;102(3):754–758. doi: 10.1111/j.1476-5381.1991.tb12245.x

Regional heterogeneity in the contractile and potentiating effects of neuropeptide Y in rat isolated coronary arteries: modulatory action of the endothelium.

D Prieto 1, S Benedito 1, U Simonsen 1, N C Nyborg 1
PMCID: PMC1917921  PMID: 1364848

Abstract

1. Neuropeptide Y (NPY) induced a concentration-dependent contraction of isolated rings of proximal epicardial (PC) and distal intramural (DC) coronary arteries of the rat, with an EC50 of ca. 1 x 10(-7) M. The NPY-induced contraction at 3 x 10(-7) M was significantly smaller in PC than DC arteries: 34% vs. 55% of the 125 mM K(+)-induced response, respectively. 2. NPY (2 x 10(-8) M) increased the sensitivity to noradrenaline (NA) and 5-hydroxytryptamine (5-HT) more in PC (4.2 and 2.8 fold, respectively) than in DC arteries (2.2 and 1.4 fold, respectively). The maximal contractile response to NA and 5-HT was increased more in DC (43% and 29%, respectively) than in PC arteries (20% and 12%, respectively). 3. Removal of the endothelium increased the sensitivity and maximal response to NPY as well as the spontaneous myogenic tone in PC but not in DC arteries. NPY had no relaxing effect on PC and DC arteries submaximally contracted with 10(-6) M prostaglandin F2 alpha, suggesting that spontaneous rather than stimulated release of endothelium-derived relaxing factor (EDRF) depresses the contractile action of NPY in PC arteries. 4. The results indicate a heterogeneity in the contractile and potentiating action of NPY in rat coronary arteries depending on size or location in the coronary circulation.

Full text

PDF
758

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aizawa Y., Murata M., Hayashi M., Funazaki T., Ito S., Shibata A. Vasoconstrictor effect of neuropeptide Y (NPY) on canine coronary artery. Jpn Circ J. 1985 Jun;49(6):584–588. doi: 10.1253/jcj.49.584. [DOI] [PubMed] [Google Scholar]
  2. Allen J. M., Gjörstrup P., Björkman J. A., Ek L., Abrahamsson T., Bloom S. R. Studies on cardiac distribution and function of neuropeptide Y. Acta Physiol Scand. 1986 Mar;126(3):405–411. doi: 10.1111/j.1748-1716.1986.tb07834.x. [DOI] [PubMed] [Google Scholar]
  3. Andriantsitohaina R., Stoclet J. C. Potentiation by neuropeptide Y of vasoconstriction in rat resistance arteries. Br J Pharmacol. 1988 Oct;95(2):419–428. doi: 10.1111/j.1476-5381.1988.tb11662.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Budai D., Vu H. Q., Duckles S. P. Endothelium removal does not affect potentiation by neuropeptide Y in rabbit ear artery. Eur J Pharmacol. 1989 Sep 1;168(1):97–100. doi: 10.1016/0014-2999(89)90638-9. [DOI] [PubMed] [Google Scholar]
  5. Daly R. N., Hieble J. P. Neuropeptide Y modulates adrenergic neurotransmission by an endothelium dependent mechanism. Eur J Pharmacol. 1987 Jun 26;138(3):445–446. doi: 10.1016/0014-2999(87)90486-9. [DOI] [PubMed] [Google Scholar]
  6. Edvinsson L., Ekblad E., Håkanson R., Wahlestedt C. Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels. Br J Pharmacol. 1984 Oct;83(2):519–525. doi: 10.1111/j.1476-5381.1984.tb16516.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Franco-Cereceda A. Endothelin- and neuropeptide Y-induced vasoconstriction of human epicardial coronary arteries in vitro. Br J Pharmacol. 1989 Jul;97(3):968–972. doi: 10.1111/j.1476-5381.1989.tb12038.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Franco-Cereceda A., Lundberg J. M., Dahlöf C. Neuropeptide Y and sympathetic control of heart contractility and coronary vascular tone. Acta Physiol Scand. 1985 Jul;124(3):361–369. doi: 10.1111/j.1748-1716.1985.tb07671.x. [DOI] [PubMed] [Google Scholar]
  9. Franco-Cereceda A., Lundberg J. M. Potent effects of neuropeptide Y and calcitonin gene-related peptide on human coronary vascular tone in vitro. Acta Physiol Scand. 1987 Sep;131(1):159–160. doi: 10.1111/j.1748-1716.1987.tb08219.x. [DOI] [PubMed] [Google Scholar]
  10. Gu J., Polak J. M., Adrian T. E., Allen J. M., Tatemoto K., Bloom S. R. Neuropeptide tyrosine (NPY)--a major cardiac neuropeptide. Lancet. 1983 May 7;1(8332):1008–1010. doi: 10.1016/s0140-6736(83)92642-9. [DOI] [PubMed] [Google Scholar]
  11. Gu J., Polak J. M., Allen J. M., Huang W. M., Sheppard M. N., Tatemoto K., Bloom S. R. High concentrations of a novel peptide, neuropeptide Y, in the innervation of mouse and rat heart. J Histochem Cytochem. 1984 May;32(5):467–472. doi: 10.1177/32.5.6546942. [DOI] [PubMed] [Google Scholar]
  12. Han C., Abel P. W. Neuropeptide Y potentiates contraction and inhibits relaxation of rabbit coronary arteries. J Cardiovasc Pharmacol. 1987 Jun;9(6):675–681. doi: 10.1097/00005344-198706000-00006. [DOI] [PubMed] [Google Scholar]
  13. Hieble J. P., Duesler J. G., Jr, Daly R. N. Effects of neuropeptide Y on the response of isolated blood vessels to norepinephrine and sympathetic field stimulation. J Pharmacol Exp Ther. 1989 Aug;250(2):523–528. [PubMed] [Google Scholar]
  14. Lundberg J. M., Hua X. Y., Franco-Cereceda A. Effects of neuropeptide Y (NPY) on mechanical activity and neurotransmission in the heart, vas deferens and urinary bladder of the guinea-pig. Acta Physiol Scand. 1984 Aug;121(4):325–332. doi: 10.1111/j.1748-1716.1984.tb07463.x. [DOI] [PubMed] [Google Scholar]
  15. Lundberg J. M., Terenius L., Hökfelt T., Goldstein M. High levels of neuropeptide Y in peripheral noradrenergic neurons in various mammals including man. Neurosci Lett. 1983 Dec 2;42(2):167–172. doi: 10.1016/0304-3940(83)90401-9. [DOI] [PubMed] [Google Scholar]
  16. Macho P., Pérez R., Huidobro-Toro J. P., Domenech R. J. Neuropeptide Y (NPY): a coronary vasoconstrictor and potentiator of catecholamine-induced coronary constriction. Eur J Pharmacol. 1989 Aug 11;167(1):67–74. doi: 10.1016/0014-2999(89)90748-6. [DOI] [PubMed] [Google Scholar]
  17. Martin S. E., Patterson R. E. Coronary constriction due to neuropeptide Y: alleviation with cyclooxygenase blockers. Am J Physiol. 1989 Sep;257(3 Pt 2):H927–H934. doi: 10.1152/ajpheart.1989.257.3.H927. [DOI] [PubMed] [Google Scholar]
  18. Maturi M. F., Greene R., Speir E., Burrus C., Dorsey L. M., Markle D. R., Maxwell M., Schmidt W., Goldstein S. R., Patterson R. E. Neuropeptide-Y. A peptide found in human coronary arteries constricts primarily small coronary arteries to produce myocardial ischemia in dogs. J Clin Invest. 1989 Apr;83(4):1217–1224. doi: 10.1172/JCI114004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Miwa K., Toda N. Regional differences in the response to vasoconstrictor agents of dog and monkey isolated coronary arteries. Br J Pharmacol. 1984 May;82(1):295–301. doi: 10.1111/j.1476-5381.1984.tb16471.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Mulvany M. J., Nyborg N. An increased calcium sensitivity of mesenteric resistance vessels in young and adult spontaneously hypertensive rats. Br J Pharmacol. 1980;71(2):585–596. doi: 10.1111/j.1476-5381.1980.tb10977.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Neild T. O. Actions of neuropeptide Y on innervated and denervated rat tail arteries. J Physiol. 1987 May;386:19–30. doi: 10.1113/jphysiol.1987.sp016519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Nyborg N. C. Action of noradrenaline on isolated proximal and distal coronary arteries of rat: selective release of endothelium-derived relaxing factor in proximal arteries. Br J Pharmacol. 1990 Jul;100(3):552–556. doi: 10.1111/j.1476-5381.1990.tb15845.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Nyborg N. C., Baandrup U., Mikkelsen E. O., Mulvany M. J. Active, passive and myogenic characteristics of isolated rat intramural coronary resistance arteries. Pflugers Arch. 1987 Dec;410(6):664–670. doi: 10.1007/BF00581329. [DOI] [PubMed] [Google Scholar]
  24. Nyborg N. C., Mikkelsen E. O. In vitro studies on responses to noradrenaline, serotonin, and potassium of intramyocardial and mesenteric resistance vessels from Wistar rats. J Cardiovasc Pharmacol. 1985 May-Jun;7(3):417–423. doi: 10.1097/00005344-198505000-00002. [DOI] [PubMed] [Google Scholar]
  25. Oshita M., Kigoshi S., Muramatsu I. Selective potentiation of extracellular Ca2+-dependent contraction by neuropeptide Y in rabbit mesenteric arteries. Gen Pharmacol. 1989;20(3):363–367. doi: 10.1016/0306-3623(89)90274-7. [DOI] [PubMed] [Google Scholar]
  26. Pernow J. Actions of constrictor (NPY and endothelin) and dilator (substance P, CGRP and VIP) peptides on pig splenic and human skeletal muscle arteries: involvement of the endothelium. Br J Pharmacol. 1989 Jul;97(3):983–989. doi: 10.1111/j.1476-5381.1989.tb12040.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Pernow J. Co-release and functional interactions of neuropeptide Y and noradrenaline in peripheral sympathetic vascular control. Acta Physiol Scand Suppl. 1988;568:1–56. [PubMed] [Google Scholar]
  28. Pernow J., Lundberg J. M. Neuropeptide Y induces potent contraction of arterial vascular smooth muscle via an endothelium-independent mechanism. Acta Physiol Scand. 1988 Sep;134(1):157–158. doi: 10.1111/j.1748-1716.1988.tb08474.x. [DOI] [PubMed] [Google Scholar]
  29. Pernow J., Svenberg T., Lundberg J. M. Actions of calcium antagonists on pre- and postjunctional effects of neuropeptide Y on human peripheral blood vessels in vitro. Eur J Pharmacol. 1987 Apr 14;136(2):207–218. doi: 10.1016/0014-2999(87)90712-6. [DOI] [PubMed] [Google Scholar]
  30. Rudehill A., Sollevi A., Franco-Cereceda A., Lundberg J. M. Neuropeptide Y (NPY) and the pig heart: release and coronary vasoconstrictor effects. Peptides. 1986 Sep-Oct;7(5):821–826. doi: 10.1016/0196-9781(86)90101-4. [DOI] [PubMed] [Google Scholar]
  31. Tseng C. J., Robertson D., Light R. T., Atkinson J. R., Robertson R. M. Neuropeptide Y is a vasoconstrictor of human coronary arteries. Am J Med Sci. 1988 Jul;296(1):11–16. doi: 10.1097/00000441-198807000-00003. [DOI] [PubMed] [Google Scholar]
  32. Wahlestedt C., Edvinsson L., Ekblad E., Håkanson R. Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action. J Pharmacol Exp Ther. 1985 Sep;234(3):735–741. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES